Pfizer's revenue and market capitalization

  •   DEHOUI Lionel

As with many companies, the year 2020 was marked by several events. For Pfizer, the development of the Covid-19 vaccine in partnership with BioNTech remains one of the highlights of the year. Apart from this, the American biopharmaceutical group recorded sales growth for the whole of the 2020 financial year. The growth that Pfizer started with did not stop. It has continued into 2021 with more than satisfactory results. Here are the details of the performances achieved by the laboratory over the year.

Trade in Pfizer shares!
79% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money. This is an advert for trading CFDs on eToro
Pfizer's revenue and market capitalization
Copyright: Montgomery County Planning Commission

Pfizer's financial results for the first quarter of 2021

In the first quarter of 2021, Pfizer Group's business has shown a remarkable improvement. For the period as a whole, the pharmaceutical company achieved a net profit of $7.864 trillion, compared to $4.877 trillion in the same period last year. This represents an increase of 61.24% compared to the same period last year.

The pharmaceutical company's earnings per share were $1.62 for the period, compared to a consensus of $1.49. With 25,661 billion in sales recorded, there was an increase of 77%. These figures are well above market expectations. Indeed, analysts were forecasting sales of 24,099 billion over this period for the firm.

Pfizer's strong performance was driven by its Covid vaccine and the availability of its anti-viral treatment, Paxlovid. The laboratory sold 1.5 billion over this period. Vaccine sales, meanwhile, rose from 3.2 billion to 13.2 billion in Q1 of fiscal 2021.

 

Sales forecast for 2021

In March 2020, Pfizer signed a partnership agreement with the German company BioNTech. This is part of the development of a vaccine against Covid-19. The American pharmaceutical group has high ambitions for the success of this vaccine.

It is the first anti-Covid vaccine authorised in the world. For the American giant, it would be one of the most profitable products in the history of the pharmaceutical industry. According to the group's forecasts at the time, sales of this vaccine should reach nearly 15 billion dollars over the whole of 2021.

This huge amount is likely to increase if Pfizer signs additional new contracts during this year. However, the US company had estimated that the sales are subject to royalties for its German partner and a fair share of the profit earned.

In addition, it should be noted that already by the end of 2020, the use of this Covid vaccine was effective in several countries around the world. In the last quarter of 2020, sales of the vaccine were estimated at approximately $154 million.

 

Performance in 2021

The US giant's sales for 2021 are estimated at $36.8 billion. The Covid-19 vaccine accounts for a large proportion (one-third) of these total sales. For the full 12 months of 2021, Pfizer generated net income of $22 billion, almost double the amount of sales achieved in the previous year. This brings the company's revenue to $81.3 billion, an increase of 95%.

For Pfizer's full fiscal year 2021, the results are higher than analysts had expected. The year 2021 was also marked by the launch of the Omicron variant. This is a version of the Covid vaccine that has gone into clinical trial.

Also in 2021, more precisely at the end of the last quarter, Pfizer launched an anti-Covid pill. It was marketed under the name Paxlovid. After the approval received for this pill at the end of December in the United States, the American giant was able to record in terms of sales, 72 million dollars in 2021 for Paxlovid.

According to the latest results published by the firm's managers, its turnover at the end of the 2021 financial year should be between 98 and 102 billion dollars. With such a figure, the adjusted earnings per share will be between 6.35 and 6.55 dollars. Unfortunately, the latter figures fall short of what analysts were expecting.

 

Pfizer Dividend and Market Capitalisation in 2021

The biopharmaceutical company Pfizer is one of the companies that regularly pays dividends to its shareholders. For more than a decade, the dividend has never fallen. Here are those distributed in 2021 with the payment dates.

  • 0.39 per share: 28 January 2021
  • 0.39 per share: 06 May 2021
  • 0.39 per share: 29 July 2021
  • 0.39 per share: 04 November 2021.

For the financial year 2022, there have already been two dividend distributions. They took place on 27 January 2022 and 12 May 2022 respectively. The dividend distributions for the year 2022 amount to $0.40 per share each. As of today, Pfizer's dividend yield is 3.05% for a payout ratio of 35.36%. This is a good level for an investment as the company does not draw on its earnings for dividend payments.

In addition, Pfizer has a strong presence in the equity markets. The company is listed on the New York Stock Exchange. In 2021, it had a market capitalisation of $290.53 billion.

 

About the Pfizer Group

Pfizer is an American biopharmaceutical company founded in 1849 and based in New York, USA. It is recognised as the world's leading pharmaceutical company. The company's goal is to innovate to create medicines that can improve the lives of patients.

The group's products include biopharmaceuticals. These include, for example, innovative medicines for the treatment of cancer and rare diseases as well as vaccines. In addition, the company is active in the manufacture of active pharmaceutical ingredients.

The company also develops generic drugs. These are used for the treatment of nervous system disorders, cardiovascular diseases, etc. In addition, the group operates in several countries. It has about 50 production sites worldwide.

Trade in Pfizer shares!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.